FSD Pharma aims to initiate a Phase 2 coronavirus treatment trial by end 2020 as it files IND
Inc () (CSE:HUGE.CN) (FRA:0K9A) CEO Raza Bokhari tells Proactive the group has submitted an Investigational New Drug (IND) application to the FDA for the use of its lead candidate FSD-201, or anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA), to treat coronavirus patients.
Bokhari says hopefully before the end of 2020, the group will initiate a Phase 2 trial to treat hospitalized coronavirus patients.
Market Cap: $50.2 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE
FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) CEO Raza Bokhari tells Proactive it has closed US$10 million in a registered direct offering. Bokhari says the offering comes as the Canadian company actively works to submit an Investigational New Drug Application to the FDA to use its FSD201 as a...